The University of Chicago Header Logo

Connection

Stephen Hanauer to Aminosalicylic Acids

Back to Details
This is a "connection" page, showing publications Stephen Hanauer has written about Aminosalicylic Acids.
Stephen Hanauer
Connection Strength
2.872
Aminosalicylic Acids
  1. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006 Nov; 4(11):1346-50.
    View in: PubMed
    Score: 0.290
  2. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:60-5.
    View in: PubMed
    Score: 0.251
  3. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord. 2004; 4(3):104-17.
    View in: PubMed
    Score: 0.239
  4. Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt. Am J Gastroenterol. 2003 Mar; 98(3):697-8.
    View in: PubMed
    Score: 0.225
  5. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis. Am J Gastroenterol. 2003 Jan; 98(1):215-6.
    View in: PubMed
    Score: 0.223
  6. Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis. Gut. 1999 Apr; 44(4):455.
    View in: PubMed
    Score: 0.172
  7. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 Jul 03; 7:CD008870.
    View in: PubMed
    Score: 0.142
  8. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am J Gastroenterol. 1993 Sep; 88(9):1343-51.
    View in: PubMed
    Score: 0.117
  9. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993 Aug; 88(8):1188-97.
    View in: PubMed
    Score: 0.116
  10. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf. 1991 May-Jun; 6(3):192-219.
    View in: PubMed
    Score: 0.099
  11. Aminosalicylates: old and new. Mt Sinai J Med. 1990 Oct; 57(5):283-7.
    View in: PubMed
    Score: 0.095
  12. The role of mesalazine in Crohn's disease. Scand J Gastroenterol Suppl. 1990; 172:56-9.
    View in: PubMed
    Score: 0.090
  13. 5-ASA enema therapy. Neth J Med. 1989 Jun; 35 Suppl 1:S11-20.
    View in: PubMed
    Score: 0.087
  14. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol. 2008 Jan 21; 14(3):354-77.
    View in: PubMed
    Score: 0.079
  15. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol. 2005 May-Jun; 39(5):390-5.
    View in: PubMed
    Score: 0.065
  16. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflamm Bowel Dis. 2005 Mar; 11(3):253-7.
    View in: PubMed
    Score: 0.065
  17. Review article: the long-term management of ulcerative colitis. Aliment Pharmacol Ther. 2004 Oct; 20 Suppl 4:97-101.
    View in: PubMed
    Score: 0.063
  18. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers. Aliment Pharmacol Ther. 2004 May 15; 19(10):1089-98.
    View in: PubMed
    Score: 0.061
  19. Medical therapy for ulcerative colitis 2004. Gastroenterology. 2004 May; 126(6):1582-92.
    View in: PubMed
    Score: 0.061
  20. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol. 2003 Dec; 98(12 Suppl):S18-23.
    View in: PubMed
    Score: 0.059
  21. Update on medical management of inflammatory bowel disease: ulcerative colitis. Rev Gastroenterol Disord. 2001; 1(4):169-76.
    View in: PubMed
    Score: 0.048
  22. Inflammatory bowel disease. N Engl J Med. 1996 Mar 28; 334(13):841-8.
    View in: PubMed
    Score: 0.035
  23. Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci. 1995 May; 40(5):931-5.
    View in: PubMed
    Score: 0.033
  24. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995 Feb; 40(2):296-304.
    View in: PubMed
    Score: 0.032
  25. Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther. 1994 Feb; 8(1):27-34.
    View in: PubMed
    Score: 0.030
  26. Medical therapy of ulcerative colitis. Lancet. 1993 Aug 14; 342(8868):412-7.
    View in: PubMed
    Score: 0.029
  27. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993 May; 104(5):1293-301.
    View in: PubMed
    Score: 0.028
  28. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology. 1988 Oct; 95(4):975-81.
    View in: PubMed
    Score: 0.021
  29. Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease. Inflamm Bowel Dis. 2004 Jul; 10 Suppl 2:S2-10.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.